177Lu-DOTATATE联合卡培他滨对比177Lu-DOTATATE单药治疗晚期1/2级胃肠胰神经内分泌肿瘤(LuCAP):一项随机2期试验
这项研究者发起的平行组开放标签2期试验将72例进展性生长抑素受体阳性的晚期1/2级胃肠胰神经内分泌肿瘤患者按1:1随机分配至177Lu-DOTATATE联合卡培他滨组或177Lu-DOTATATE单药组。联合组客观缓解率为33.3%,单药组为30.6%(P=0.800),两组无显著差异;疾病控制率、无进展生存期和总生存期均无显著差异。结论认为在晚期1/2级胃肠胰神经内分泌肿瘤中,联合低剂量卡培他滨并未带来更优的影像学缓解。
要点
- 联合组客观缓解率33.3% vs 单药组30.6%(P=0.800),无显著差异。
- 联合组疾病控制率88.9% vs 单药组91.7%(P=1.000),无显著差异。
- 联合组中位无进展生存期29个月 vs 单药组31个月(P=0.401),无显著差异。
核心结论
- 在晚期1/2级胃肠胰神经内分泌肿瘤中,177Lu-DOTATATE联合低剂量卡培他滨未带来更优的影像学缓解。
- 原文结论指出需进一步研究评估其在高分级神经内分泌肿瘤中的潜在作用。
研究设计与样本
- 研究者发起的平行组开放标签2期随机对照试验。
- 纳入72例1/2级胃肠胰神经内分泌肿瘤患者,68Ga-DOTANOC PET/CT示生长抑素受体阳性、局部晚期或转移性且进展。
- 按1:1随机分配至177Lu-DOTATATE联合卡培他滨组(实验组)或177Lu-DOTATATE单药组(对照组)。
- 177Lu-DOTATATE约7.4 GBq/周期静脉给药,最多4个周期,间隔8周;卡培他滨1,250 mg/m2/d口服,每周期第0天至第14天。
- 主要终点为客观缓解率;次要终点包括疾病控制率、无进展生存期、总生存期和不良事件。
主要发现
- 中位年龄53岁(范围18-79岁)。
- 客观缓解率实验组33.3%(95%CI 18.6-50.9%)vs 对照组30.6%(95%CI 16.4-48.1%),P=0.800。
- 疾病控制率实验组88.9%(95%CI 73.9-96.9%)vs 对照组91.7%(95%CI 77.5-98.2%),P=1.000。
- 估计中位无进展生存期实验组29个月(95%CI 22-29个月)vs 对照组31个月(95%CI 29-32个月),P=0.401。
- 两组中位总生存期均未达到(P=0.876);至少3级不良事件实验组7例 vs 对照组6例(P=0.759)。
关键数值与推荐
- 原文未报告指南或共识推荐条款。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究评估177Lu-DOTATATE联合低剂量卡培他滨在高分级神经内分泌肿瘤中的潜在作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant 177Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials. Methods: In this investigator-initiated, parallel-group, open-label, phase 2 trial, patients with grade 1/2 GEP-NETs, having progressive somatostatin receptor-positive, locally advanced, or metastatic disease on 68Ga-DOTANOC PET/CT, were randomly assigned in a 1:1 ratio to 177Lu-DOTATATE plus capecitabine (experimental arm) or 177Lu-DOTATATE only (control arm). 177Lu-DOTATATE was administered at approximately 7.4 GBq/cycle intravenously, for up to 4 cycles, at 8 wk intervals, whereas capecitabine was given at 1,250 mg/m2/d orally from day 0 to day 14 of each cycle of 177Lu-DOTATATE. The primary endpoint was the objective response rate. Secondary endpoints included the disease control rate, progression-free survival, overall survival, and adverse events. Results: Seventy-two patients (median age, 53 y; range, 18-79 y) were enrolled. The objective response rate was 33.3% (95% CI, 18.6-50.9%) in the experimental arm versus 30.6% (95% CI, 16.4-48.1%) in the control arm (P = 0.800). The disease control rate was 88.9% (95% CI, 73.9-96.9%) and 91.7% (95% CI, 77.5-98.2%) in the experimental and control arms, respectively (P = 1.000). The estimated median progression-free survival in the experimental arm was 29 mo (95% CI, 22-29 mo) versus 31 mo (95% CI, 29-32 mo) in the control arm (P = 0.401). The median overall survival was not reached in either arm (P = 0.876). Overall, adverse events of at least grade 3 were noted in 7 patients in the experimental arm versus 6 patients in the control arm (P = 0.759). Conclusion: Based on the results of this trial, the addition of low-dose capecitabine to 177Lu-DOTATATE in advanced grade 1/2 GEP-NETs did not lead to superior radiographic responses. Further studies are needed to evaluate its potential role in high-grade NETs.
引用
- Satapathy S, Aggarwal P, Sood A, et al. 177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial. J Nucl Med. 2025. PMID: 39778968. doi:10.2967/jnumed.124.268617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。